Design Therapeutics to Host Investor Webcast to Review Data from RESTORE-FA Trial of DT-216P2 for Friedreich’s Ataxia on Monday, May 18, 2026
Design Therapeutics will announce data from its ongoing Phase 1/2 RESTORE-FA trial of DT-216P2 for Friedreich’s ataxia on Monday, May 18, 2026. Management will host a conference call and webcast at 8:00 a.m. ET to review the results.
Key figures
- Drug Name
- DT-216P2
- Phase Of Trial
- Phase 1/2
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.